Medtronic has received the US Food and Drug Administration (FDA) approval for its Consulta and Syncra cardiac resynchronization therapy-pacemaker (CRT-P) systems.
Consulta includes company’s OptiVol Fluid Status Monitoring, which identifies patients at risk for worsening heart failure before symptoms develop and Complete Capture Management, which monitors and adjusts to patient needs automatically, and can positively impact device longevity and reduce in-office testing.
Medtronic said both Consulta and Syncra include Leadless ECG Waveform, which together with the Medtronic CareLink Network device data monitoring system, offer the possibility of remote follow-up in heart failure patients implanted with these devices.
Both systems provide fully automatic capabilities and adaptive therapies that help to ensure CRT, even during atrial fibrillation, and enable physicians to monitor their heart failure patients in the office or remotely.
Additionally, both systems include programming flexibility to avoid phrenic nerve stimulation, which helps prevent the need for more invasive surgical approaches.